Abstract
Riboflavin deficiency diminishes the rate of growth of spontaneous tumors in experimental animals but enhances the carcinogenicity of specific drugs such as the azo dyes, which are degraded by a microsomal hydroxylase system requiring riboflavin. Human esophageal cancer has been epidemiologically associated with riboflavin deficiency, but the precise role of riboflavin in this tumor remains to be defined. Riboflavin nutriture influences epithelial integrity, tissue flavin concentrations, rates of prostaglandin biosynthesis, and glutathione metabolism, each of which may have implications for carcinogenesis.
Supported in part by the Clinical Nutrition Research Unit Grant 5 POl CA 29502 from the National Institutes of Health, National Cancer Institute Cancer Core Grant CA 08748, and grants from the Stella and Charles Guttman Foundation, the William H. Donner Foundation, National Dairy Council, Distilled Spirits Council of the United States, Alcoholic Beverage Medical Research Foundation, and General Foods Fund. Research was performed in the Sperry Corporation Nutrition Research Laboratory.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Abbreviations
- FAD:
-
flavin adenine dinucleotide
- FMN:
-
flavin mononucleotide
References
H. P. Morris and W. V. B. Robertson, Growth rate and number of spontaneous mammary carcinomas and riboflavin concentration of liver, muscle, and tumor of C3H mice as influenced by dietary riboflavin, J. Natl. Cancer Inst. 3:479 (1943).
H. P. Morris, Effects on the genesis and growth of tumors associated with vitamin intake, Ann. N.Y. Acad. Sci. 49:119 (1947).
R. S. Rivlin, Riboflavin and cancer: A review, Cancer Res. 33:1977 (1973).
H. C. Stoerck and G. A. Emerson, Complete regression of lymphosarcoma implants following temporary induction of riboflavin deficiency in mice, Proc. Soc. Exp. Biol. Med. 70:703 (1949).
N. V. Aposhian and J. P. Lambooy, Retardation of growth of Walker rat carcinoma 256 by administration of diethyl riboflavin, Proc. Soc. Exp. Biol. Med. 78:197 (1951).
R. S. Rivlin, T. Homibrook, and M. Osnos, Effects of riboflavin deficiency upon concentrations of riboflavin, flavin mononucleotide and flavin adenine dinucleotide in Novikoff hepatoma in rats, Cancer Res. 33:3019 (1973).
Y. S. Kim, M. M. Aposhian, and J. P. Lambooy, The influence of homologs of riboflavin on the growth of Walker rat carcinoma 256, Cancer Res. 26:1344 (1956).
J. A. Miller and E. C. Miller, Carcinogenic azo dyes, Adv. Cancer Res. 1:339 (1953).
S. Fass and R. S. Rivlin, Regulation of riboflavin-metabolizing enzymes in riboflavin deficiency, Am. J. Physiol. 217:988 (1969).
H. M. Nizami and F. Nizami, On the protective role of vitamin B2 in mice administered dimethylnitrosamine, J.P.M.A. 29:141 (1979).
M. Ohkoshi, H. Ohta, and M. Ito, Effect of vitamin B2 on tumorigenesis of 3-methylcholanthrene in the mouse skin, Gann 73:105 (1982).
C. S. Catz, M. R. Juchau, and S. J. Yaffe, Effects of iron, riboflavin and iodine deficiencies on hepatic drug-metabolizing enzyme systems, J. Pharmacol. Exp. Ther. 174:197 (1970).
M. Lane, F. E. Smith, and C. P. Alfrey, Jr., Experimental dietary and antagonist-induced human riboflavin deficiency, in: “Riboflavin,“ R. S. Rivlin, eds., Plenum Press, New York (1975).
M. Farhangi and E. F. Osserman, Myeloma with xanthoderma due to an IgG, monoclonal anti-flavin antibody, N. Engl. J. Med. 294:177 (1976).
A. G. Fazekas, C. E. Menendez, and R. S. Rivlin, A competitive protein binding assay for urinary riboflavin, Biochem. Med. 9:167 (1974).
J. Kmet, D. S. McLaren, and F. Siassi, Epidemiology of esophageal cancer with special reference to nutritional studies among the turkoman of Iran, in: “Role of Nutrition in Obesity and Disease,“ R. B. Tobin and M. A. Mehlman, eds., Pathotox Publishers, Park Forest South, I11. (1980).
D. I. Thurnham, P. Rathakette, K. M. Hambidge, et al., Riboflavin, vitamin A and zinc status in Chinese subjects in a high-risk area of esophageal cancer in China, Human Nutr. Clin. Nutr. 36C:337 (1982).
S. H. Lu and P. Lin, Recent research on the etiology of esophageal cancer in China, Z. Gastroenterol. 20:361 (1982).
R. G. Ziegler, L. E. Morris, W. J. Blot, et al., Esophageal cancer among black men in Washington, D.C. II. Role of nutrition, J. Natl. Cancer Inst. 67:1199 (1981).
S. J. Van Rensburg, A. S. Benade, E. F. Rose, et al., Nutritional status of African populations predisposed to esophageal cancer, Nutr. Cancer 4:206 (1983).
E. L. Wynder and J. H. Fryer, Study of etiological factors in Plummer-Vinson syndrome, Ann. Intern. Med. 49:1106 (1958).
E. L. Wynder and U. E. Klein, The possible role of riboflavin deficiency in epithelial neoplasia. I. Epithelial changes in mice in simple deficiency, Cancer 18:167 (1965).
G. Goldsmith, Riboflavin deficiency, in: “Riboflavin,“ R. S. Rivlin, ed., Plenum Press, New York (1975).
R. S. Rivlin, A. G. Fazekas, and R. Chaudhuri, Experimental approaches to the pathogenesis of cancer-induced cachexia, in: “Frontiers of Internal Medicine,“ S. H. Blondheim, ed., S. Karger, Basel (1975).
R. S. Rivlin, M. E. Shils, and P. Sherlock, Nutrition and cancer: Combined clinical and basic science seminar, Am. J. Med. 75:843 (1983).
R. S. Rivlin, Riboflavin and cancer, in: “Riboflavin,“ R. S. Rivlin, ed., Plenum Press, New York (1975).
N. J. Pelliccione, R. Karmali, R. S. Rivlin, et al., Effects of riboflavin deficiency upon prostaglandin biosynthesis in rat kidney, Prostaglandins Leukotrienes Med. 17:349 (1985).
S. E. Olpin and C. J. Bates, Lipid metabolism in riboflavin-deficient rats. 1: Effect of dietary lipids on riboflavin status and fatty acid profiles, Br. J. Nutr. 47:577 (1982).
S. A. Metz, J. R. McRae, and R. P. Robertson, Prostaglandins as mediators of paraneoplastic syndromes: Review and update, Metabolism 30:299 (1981).
H. J. Powers and P. I. Thurnham, Riboflavin deficiency in man: Effect on haemoglobin and reduced glutathione in erythrocytes of different ages, Br. J. Nutr. 46:257 (1981).
R. S. Rivlin, C. Menendez, and R. G. Langdon, Biochemical similarities between hypothyroidism and riboflavin deficiency, Endocrinology 83:461 (1968).
A. M. Prentice and C. J. Bates, A biochemical evaluation of the erythrocyte glutathione reductase (EC 1.6.4.2) test for riboflavin status. I. Rate and specificity of response in acute deficiency, Br. J. Nutr. 45:37 (1981).
R. F. Burk, M. J. Trumble, and R. A. Lawrence, Rat hepatic cytosolic glutathione-dependent enzyme protection against lipid peroxidation in the NADPH-microsomal lipid peroxidation system, Biochim. Biophys. Acta 618:35 (1980).
M. Younes and C. P. Siegers, Mechanistic aspects of enhanced lipid peroxidation following glutathione depletion in vivo, Chem. Biol. Interact. 34:257 (1981).
C. Carruthers and A. Baumler, Distribution of ligandin in normal and azocarcinogen-treated rat liver and azocarcinogen-induced liver tumors, Oncology 36:265 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Rivlin, R.S. (1986). Riboflavin. In: Poirier, L.A., Newberne, P.M., Pariza, M.W. (eds) Essential Nutrients in Carcinogenesis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1835-4_26
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1835-4_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9025-4
Online ISBN: 978-1-4613-1835-4
eBook Packages: Springer Book Archive